Gilead Sciences (GILD) has seen its shares rise following positive second-quarter results and a new artificial intelligence collaboration with Nucleai. Despite the positive developments, analysis suggests the stock could be approximately 8% overvalued.
Gilead Sciences Shares Rise on Q2 Results, AI Deal; Valuation Concerns Emerge
|1 min read
GILDQ2-earningsAI-collaborationbiotechvaluation
